101 research outputs found
D02. NCNPR Activities at Coy Waller Complex
No full textCorresponding author (NCNPR, School of Pharmacy): Mohamed M. Radwan, [email protected]://egrove.olemiss.edu/pharm_annual_posters/1024/thumbnail.jp
Poetry ars divina: Musaeus’ Prophetic Oration in the Epic Poem Radivilias by Jan Radwan
No full textHeroic epic poem entitled Radivilias sive de vita et moribus praeclarissime gestis immortalis memoriae illustrissimi principis Nicolai Radivili … libri quattuor, by Jan Radwan, was published in Vilnius in 1592.
The historical narration about the chief events connected with the Livonian War (1558-1582) when Poland and the Great Duchy of Lithuania were struggling against Ivan, the Terrible serves as a setting for a panegyric portrait of the main hero of the poem, Mikołaj Radziwiłł, the Red and his heroic deeds.
The author of Radivilias takes Radziwiłł to Helicon, place sacred to a succession of poetic memories, where he meets Musaeus. This part of the poem resembles Cicero’s Dream of Scipio, but we can see an essential difference between these two texts (Cicero - dream, dead ancestors, rational justification, Radwan - mythological motif, legendary poet Musaeus and poetry as a source of wisdom). Radwan is very realistic. He does not dream about return of the Golden Age, but emphasises the fragility of earthly glory and concentrates his attention upon the only true life - the life after death.
This article aims at discussing Radwan’s conception of the function of the Musaeus’ prophecy in the whole context of the poem. The attention is being given also to a prohetic significance of poetry
Marian Radwan, Ecclesiastica w Rosyjskim Państwowym Archiwum Historycznym w Sankt Petersburgu : recenzija
No full textRecenzuojama knyga skirta ne plačiajai skaitytojų auditorijai, bet neabejotinai verta Lietuvos istorikų, tyrinėjančių Lietuvos Bažnyčios istorijos bei XIX–XX a. religinio gyvenimo peripetijas, dėmesio. Rusijos valstybiniame istorijos archyve (RVIA) Sankt Peterburge didelį darbą atlikusio lenkų profesoriaus Mariano Radwano veiklą vainikuoja naujas žinynas, kuriame pristatomi RVIA esantys vadinamieji bažnytiniai fondai. Žinyne apsiribojama katalikų ir unitų Bažnyčių istoriją atskleidžiančiais archyviniais šaltiniais. Įvadiniame straipsnyje autorius trumpai aptaria katalikų ir unitų istorijai svarbius RVIA fondus, pateikia apie juos glaustus duomenis ir pagrindinius skaičius, pristato žinyno sudarymo principus. Dėmesį sutelkęs ties dviem Bažnyčiomis – katalikų ir unitų, autorius žinyne pagrįstai išskiria du stambius skyrius: Romos katalikų Bažnyčios archyvai ir Graikų katalikų Bažnyčios archyvai, kiekviename jų pateikdamas atskirus teminius blokus pagal fondus. Daugiausia teminių blokų autorius išskyrė Kitatikių dvasinių reikalų departamento fonde. Pavadinimai įvardija dokumentų turinį, o išdėstymas pagal abėcėlę palengvina paiešką. Tarp baigiamųjų įvadinio straipsnio eilučių galima įskaityti, kad RVIA vadovybės palaikymo žinyno autorius neturėjo. Turint tai omenyje, žinynas įgauna dar ir kitą vertę, tapdamas vaizdžiu dabartinės katalikų Bažnyčios situacijos sparčiai sekuliarėjančiam pasauly istorijos faktu. Reikšminiai žodžiai: Ekleziastika; Ekleziologija; Katalikų ir unitų Bažnyčios dokumentai; M. Radwan; RVIA; Sankt Peterburgo valstybinis istorinis archyvas; Documents Catholic and Uniate Churches; Ecclesiastica; Ecclesiology; M. Radwan; Russian state archive; State Historical Archives of St. PetersburgThe reviewed book is not targeted at a wide audience, but is definitely worth the attention of Lithuanian historians who investigate the peripaetia of the history of the Lithuanian Church and the religious life in the 19th–20th c. The activities of Polish Professor Marian Radwan, who did a huge work in the Russian State Historical Archive (RSHA) in Saint Petersburg, have been crowned by a new directory which presents the church stocks kept at the RSHA. The directory is limited to the archival sources revealing the history of the Catholic and Uniate Churches. The introductory article briefly discusses the RSHA stocks relevant to the history of Catholics and Uniates, gives concise data and key figures and presents the principles of the structure of the directory. Focusing on two Churches – Catholic and Uniate – the author reasonably distinguishes two large chapters: the archives of the Roman Catholic Church and the archives of the Greek Catholic Church. Each chapter contains thematic units according to the stocks. The stocks of the Department for Spiritual Affairs of Foreign Confessions have the biggest number of thematic units. The titles name the content of documents and the alphabetical order facilitates the search. The final lines of the introductory article inform that the author of the directory received no support from the RSHA management. With this in mind, the directory acquires additional value by becoming an ostensive historical fact of the current Catholic Church situation in the rapidly secularising world
The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1
No full textAbstract Background The ability to distinguish hepatocellular carcinoma (HCC) from metastatic carcinoma (MC) involving the liver and cholangiocarcinoma (CC) by immunohistochemistry has been limited by the lack of a reliable positive marker for hepatocellular differentiation. Arginase-1 is a marker for HCC recently described in some literature. Aim To examine the immunohistochemical staining of arginase-1 in cases of HCC, MC involving the liver and CC as compared to hepatocyte paraffin antigen -1 (HepPar-1) in an attempt to further define the diagnostic utility of arginase-1 in differentiating these tumors. Materials and methods A comparative immunohistochemical study of arginase-1 and HepPar-1expression was performed in 50 HCC cases, 38 cases of MC to the liver from varying sites, 12 cases of CC and 10 specimens of normal liver tissues. The predictive capacity of arginase-1 and HepPar-1 staining was determined using sensitivity, specificity, positive predictive value, and negative predictive value calculations. Results All normal liver tissues (no=10), non- neoplastic cirrhotic liver tissues adjacent to HCC (no=42) as well as those adjacent to MC (no= 9) showed diffuse and strong immunostaining for both arginase-1 and HepPar-1. Arginase-1 demonstrated positive immunoreactivity in 42 of 50 (84%) cases of HCC compared with 35 of 50 (70%) for HepPar-1. Only one of 38 (2.6%) cases of MC and one of 12 (8.3%) cases of CC showed positive immunoreactivity for arginase-1. In contrast, HepPar-1 immunoreactivity was detected in 6 of 38 (15.8%) cases of MC and in 2 of 12 (16.7%) cases of CC. Arginase -1 showed a significantly higher sensitivity for HCC diagnosis (84%) compared to HepPar -1(70%) (p=0.016). The specificity of arginase-1 for HCC diagnosis was higher (96%) than that of HepPar -1 (84%); nevertheless, this was not statistically significant (p=0.109). Howerver, the combination of both immunomarkers for the diagnosis of HCC, raised the specificity to 100%. Conclusion Arginase-1 immunostaining has a higher sensitivity and specificity than HepPar-1 for HCC diagnosis. Furthermore, the combined use of arginase-1 and HepPar-1 can provide a potentially promising tool to improve the accuracy in distinguishing HCC from metastatic carcinoma and cholangiocarcinoma. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9991436558072434.</p
Harmonization of land registry in Europe
No full textAn increase in cross-border transactions of immovable property within the European Union puts a demand for easy access to the information of the national land administrations of the member states. The European Union Land Information System (EULIS) project brings together the registrations of eight European jurisdictions in one portal. In this way it provides cross-border access to information about the rights on real estate, using the information in thecomputerized databases of the participating land registries. The EULIS project is the first step towards a more transparent system of real estate transactions. The next logical step, from the viewpoint of international accessibility of the information, is that the national land registries within the united Europe will be harmonized or even integrated in one European land registry or administration.In order to promote cross-border transactions and to facilitate the European mortgage market the authors suggest the introduction of a common way of land registration, in addition to the existing national land registrations: the EuroTitle system. This is a challenging concept, which may bring the required uniformity of land registration in Europe. This approach is in the beginning stages of development and the legal and organisational consequences need to be further explored and developed in order to assess the feasibility of the introduction of such a concept in European land registry.OLD Geo-information and Land Developmen
β-Thalassemia intermedia: A bird'S-eye view [β-Talasemi i̇ntermedya: Kuşbaki[dotless]şi[dotless]]
No full textBeta-thalassemia is due to a defect in the synthesis of the beta-globin chains, leading to alpha-beta imbalance, ineffective erythropoiesis, and chronic anemia. The spectrum of thalassemias is wide, with one end comprising thalassemia minor, which consists of a mild hypochromic microcytic anemia with no obvious clinical manifestations, while on the other end is thalassemia major, characterized by patients who present in their first years of life with profound anemia and regular transfusion requirements for survival. Along the spectrum lies thalassemia intermedia, a term developed to describe patients with manifestations that are neither mild enough nor severe enough to be classified in the spectrum's extremes. Over the past decade, our understanding of β-thalassemia intermedia has increased tremendously with regards to molecular information as well as pathophysiology. It is now clear that β-thalassemia intermedia has a clinical presentation as well as complications associated with the disease that are different from those of β-thalassemia major. This review is designed to tackle issues related to β-thalassemia intermedia from the basic definition of the disease to paramedical issues, namely the quality of life in these patients. Genetics and pathophysiology are revisited, as well as the complications specific to this disease. These complications include effects on several organ systems, including the cardiovascular, hepatic, endocrine, renal, brain, and skeletal systems. Extramedullary hematopoiesis is also discussed in this article. Risk factors are highlighted and cutoffs are identified to minimize morbidities in β-thalassemia intermedia. Several treatment modalities are considered by shining a light on the pros and cons of each modality, as well as the role of special pharmacological agents in the progress of the disease and its morbidities. Finally, health-related quality of life is discussed in these patients with a direct comparison to the more severe β-thalassemia major.Aessopos A, 2007, ATHEROSCLEROSIS, V191, P427, DOI 10.1016-j.atherosclerosis.2006.04.015; Aessopos A, 2006, ANN THORAC SURG, V81, P2037, DOI 10.1016-j.athoracsur.2006.01.026; Atichartakarn V, 2003, INT J HEMATOL, V78, P139, DOI 10.1007-BF02983382; Borgna-Pignatti C, 2010, ANN NY ACAD SCI, V1202, P214, DOI 10.1111-j.1749-6632.2010.05550.x; Borgna-Pignatti C, 2007, BRIT J HAEMATOL, V138, P291, DOI 10.1111-j.1365-2141.2007.06654.x; Brandt HRC, 2009, BRIT J DERMATOL, V160, P202, DOI 10.1111-j.1365-2133.2008.08894.x; Brannan D, 1927, B JOHNS HOPKINS HOSP, V41, P104; Brenner BM, 1996, KIDNEY INT, V49, P1774, DOI 10.1038-ki.1996.265; BREZIS M, 1995, NEW ENGL J MED, V332, P647; CAMASCHELLA C, 1995, HAEMATOLOGICA, V80, P58; CAMASCHELLA C, 1995, AM J HEMATOL, V48, P82; Cao A, 2013, CSH PERSPECT MED, V3, DOI 10.1101-cshperspect.a011775; Cappellini MD, 2009, DISORDERS ERYTHROPOI; Cappellini MD, 2005, SEMIN HEMATOL S1, V42, P19; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Cappellini MD, 2001, HAEMATOLOGICA S1, V86, P194; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Chuang CK, 1998, J FORMOS MED ASSOC, V97, P431; Cooley TB, 1927, AM J DIS CHILD, V34, P347; Crary SE, 2009, BLOOD, V114, P2861, DOI 10.1182-blood-2009-04-210112; DAVIS LE, 1991, AM J PHYSIOL, V261, pR1542; Derchi G, 2014, CIRCULATION, V129, P338, DOI 10.1161-CIRCULATIONAHA.113.002124; Dixit A, 2005, ANN HEMATOL, V84, P441, DOI 10.1007-s00277-005-1026-4; DORE F, 1993, AM J HEMATOL, V44, P148, DOI 10.1002-ajh.2830440216; Dore F, 1992, Ann Ital Med Int, V7, P137; Galanello R, 1998, ANN NY ACAD SCI, V850, P325, DOI 10.1111-j.1749-6632.1998.tb10489.x; GALANELLO R, 1994, BLOOD, V83, P561; GIMMON Z, 1982, PLAST RECONSTR SURG, V69, P320, DOI 10.1097-00006534-198202000-00023; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038-nm0503-496; Gladwin MT, 2008, NEW ENGL J MED, V359, P2254, DOI 10.1056-NEJMra0804411; Habib A, 2008, HAEMATOL-HEMATOL J, V93, P941, DOI 10.3324-haematol.12460; Haidar R, 2010, EUR SPINE J, V19, P871, DOI 10.1007-s00586-010-1357-2; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hershko C, 2010, ANN NY ACAD SCI, V1202, P1, DOI 10.1111-j.1749-6632.2010.05544.x; Heyman SN, 2008, AM J NEPHROL, V28, P998, DOI 10.1159-000146075; HMIDA S, 1994, NOUV REV FR HEMATOL, V36, P363; INGRAM VM, 1959, NATURE, V184, P1903, DOI 10.1038-1841903a0; Karimi M, 2005, J PEDIAT HEMATOL ONC, V27, P380, DOI 10.1097-01.mph.0000174386.13109.28; Khan S, 1999, LAB INVEST, V79, P1089; Khoury B, 2012, INT J PSYCHIAT MED, V44, P291, DOI 10.2190-PM.44.4.a; KUMAR A, 1995, SEMIN ROENTGENOL, V30, P99, DOI 10.1016-S0037-198X(05)80027-6; LAFFERTY HM, 1991, AM J KIDNEY DIS, V17, P2; Levin C, 2011, ISR MED ASSOC J, V13, P316; Li XP, 2011, J NEURAL TRANSM, V118, P473, DOI 10.1007-s00702-010-0518-0; Logothetis J, 1972, NEUROLOGY, V22, P249; Maakaron JE, 2013, ANN HEPATOL, V12, P142; Maakaron Joseph E, 2013, J Med Liban, V61, P175; Manfre L, 1999, AM J ROENTGENOL, V173, P1477; MASTRANGELO F, 1975, NEPHRON, V14, P229, DOI 10.1159-000180452; Musallam KM, 2012, BLOOD CELL MOL DIS, V49, P136, DOI 10.1016-j.bcmd.2012.06.001; Musallam KM, 2011, EUR J HAEMATOL, V87, P73, DOI 10.1111-j.1600-0609.2011.01623.x; Musallam KM, 2011, BLOOD CELL MOL DIS, V47, P232, DOI 10.1016-j.bcmd.2011.07.005; Musallam KM, 2011, HAEMATOL-HEMATOL J, V96, P1605, DOI 10.3324-haematol.2011.047852; Musallam KM, 2012, CSH PERSPECT MED, V2, DOI 10.1101-cshperspect.a013482; Musallam KM, 2012, BLOOD, V120; Musallam KM, 2012, THROMB RES, V130, P695, DOI 10.1016-j.thromres.2012.07.013; Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681-ASN.2005070757; Neufeld EJ, 2012, BLOOD, V119, P3263, DOI 10.1182-blood-2011-10-386268; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046-j.1523-1755.2000.00419.x; Norman JT, 1999, EXP NEPHROL, V7, P463; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056-NEJM199907083410207; Olivieri NF, 1996, SEMIN HEMATOL, V33, P24; Origa R, 2008, HAEMATOL-HEMATOL J, V93, P1095, DOI 10.3324-haematol.12484; Origa R, 2007, HAEMATOL-HEMATOL J, V92, P583, DOI 10.3324-haematol.10842; Pakbaz Z, 2005, ANN NY ACAD SCI, V1054, P457, DOI 10.1196-annals.1345.059; Panigrahi I, 2005, HEMATOLOGY, V10, P61, DOI 10.1080-10245330400020439; PARSA K, 1995, J NEUROSURG, V82, P657, DOI 10.3171-jns.1995.82.4.0657; Phrommintikul A, 2006, HEART, V92, P1467, DOI 10.1136-hrt.2005.079970; PIPPARD MJ, 1982, BLOOD, V60, P288; Ponticelli C, 2010, BLOOD REV, V24, P239, DOI 10.1016-j.blre.2010.08.004; Pootrakul P, 2003, BRIT J HAEMATOL, V122, P305, DOI 10.1046-j.1365-2141.2003.04412.x; PRABHAKAR S, 1980, SURG NEUROL, V13, P351; Quinn CT, 2011, BRIT J HAEMATOL, V153, P111, DOI 10.1111-j.1365-2141.2010.08477.x; Ricchi P, 2012, BLOOD CELL MOL DIS, V49, P133, DOI 10.1016-j.bcmd.2012.05.012; Richter E, 1993, Aktuelle Radiol, V3, P320; Rienhoff HY, 2011, HAEMATOL-HEMATOL J, V96, P521, DOI 10.3324-haematol.2010.034405; ROSS P, 1969, AMER J ROENTGENOL RA, V106, P604; Rund D, 2005, NEW ENGL J MED, V353, P1135, DOI 10.1056-NEJMra050436; Salehi SA, 2004, SPINAL CORD, V42, P117, DOI 10.1038-sj.sc.3101544; SHIN KH, 1994, ACTA HAEMATOL-BASEL, V91, P154; SONAKUL D, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P516; SPANOS T, 1990, VOX SANG, V58, P50; St Pierre TG, 2005, BLOOD, V105, P855, DOI 10.1182-blood-2004-01-0177; STURGEON P, 1955, BRIT J HAEMATOL, V1, P264, DOI 10.1111-j.1365-2141.1955.tb05509.x; Sumboonnanonda A, 2003, PEDIATR NEPHROL, V18, P257, DOI 10.1007-s00467-003-1067-7; Sumiyoshi A, 1992, Southeast Asian J Trop Med Public Health, V23 Suppl 2, P29; Taher A, 2008, HAEMATOL-HEMATOL J, V93, P1584, DOI 10.3324-haematol.13098; Taher A, 2006, BLOOD CELL MOL DIS, V37, P12; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; Taher A, 2009, BRIT J HAEMATOL, V147, P634, DOI 10.1111-j.1365-2141.2009.07848.x; Taher AT, 2008, BLOOD REV, V22, P283, DOI 10.1016-j.blre.2008.04.001; Taher AT, 2013, ANN HEMATOL, V92, P1485, DOI 10.1007-s00277-013-1808-z; Taher AT, 2010, AM J HEMATOL, V85, P288, DOI 10.1002-ajh.21626; Taher AT, 2010, BRIT J HAEMATOL, V150, P486, DOI 10.1111-j.1365-2141.2010.08220.x; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111-j.1365-2141.2010.08486.x; Taher AT, 2010, J THROMB HAEMOST, V8, P2152, DOI 10.1111-j.1538-7836.2010.03940.x; Taher AT, 2010, J THROMB HAEMOST, V8, P54, DOI 10.1111-j.1538-7836.2009.03651.x; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182-blood-2009-09-243154; Tanaka T, 2003, KIDNEY INT, V64, P2020, DOI 10.1046-j.1523-1755.2003.00301.x; Thalassemia International Federation, 2004, GUID CLIN MAN THAL; Treadwell MJ, 2001, SEMIN HEMATOL, V38, P77, DOI 10.1053-shem.2001.20148; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; WEATHERALL DJ, 1980, TEX REP BIOL MED, V40, P323; WEATHERA.DJ, 1965, NATURE, V208, P1061, DOI 10.1038-2081061a0; Weatherall DJ, 2011, TRANSFUSION MED, V21, P218, DOI 10.1111-j.1365-3148.2011.01090.x; Weatherall DJ, 2004, NAT REV GENET, V5, P625, DOI 10.1038-nrg1406; Whipple GH, 1936, J PEDIATR, V9, P279, DOI 10.1016-S0022-3476(36)80021-3; Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182-blood-2004-10-3982; Zeisberg M, 2000, J NEPHROL S3, V13, P11111
Genetic predictors and fitness consequences of male attractiveness in the guppy (Poecilia reticulata)
No full textWydział BiologiiU gatunków, u których nie ma bezpośrednich korzyści z wyboru partnera, samice kojarząc się z atrakcyjnymi samcami mogą zyskać pośrednie korzyści genetyczne w postaci potomstwa o wysokim dostosowaniu – atrakcyjnych synów (model Fisher’a) lub wysokiej jakości potomstwo („dobre geny”). Oba modele przewidują, że atrakcyjne samce powinny mieć więcej wnuków. Jednak te przewidywania są rzadko testowane. L. wnuków jest dokładniejszą miarą dostosowania, ponieważ odzwierciedla komponenty dostosowania potomstwa oraz potencjalne kompromisy ewolucyjne i konflikty płciowe (KP). W związku z tym badania w niniejszej rozprawie doktorskiej sprawdzały: 1) czy cechy atrakcyjne (epigamiczne) samców przewidują, nie tylko sukces kojarzeniowy (SK) i sukces reprodukcyjny (SR), ale, co ważniejsze, l. wnuków; 2) czy samce o wysokim dostosowaniu mają więcej wnuków mimo potencjalnych KP; oraz 3) założenia hipotezy „dobre geny jako heterozygotyczność”, poprzez zbadanie, czy 2 potencjalne kategorie „dobrych genów” – heterozygotyczność ogólnogenomową (MLH) i geny głównego układu zgodności tkankowej (MHC) wpływają na komponenty dostosowania i cechy epigamiczne samców. Wyniki wykazały, że: 1) cechy epigamiczne przewidywały dostosowanie samców mierzone l. wnuków, ale nie SK czy SR; 2) samce o wysokim dostosowaniu miały więcej wnuków i synów o wysokim SR, ale córki o zmniejszonym RS; 3) MLH było odziedziczalne i przewidywało dostosowanie na podstawie l. wnuków, ale nie przewidywało SK ani SR. Podsumowując, wyniki podkreślają, że wnioskowanie o korzyściach z wyboru partnera na podstawie SR może być niekompletne lub mylące. Włączenie kolejnych pokoleń do badań nad doborem płciowym dostarcza bardziej wiarygodnego oszacowania dostosowania.In species in which males do not provide females with direct benefits from mate choice, females by mating with attractive males may gain indirect genetic benefits in terms of offspring of high-fitness – attractive sons (Fisherian benefits) or high quality progeny (‘good genes’). Both of these models predict that attractive males should have more grandoffspring. However, this prediction has rarely been tested. No. of grandoffspring is a more accurate measure of fitness as it captures fitness components of the progeny, possible life-history trade-offs or intralocus sexual conflict (IASC). Therefore, studies in this PhD thesis tested: 1) if male epigamic traits predict not only mating (MS) and reproductive success (RS), but most importantly, no. of grandoffspring; 2) if high-fitness males have more grandoffspring despite potential IASC; and 3) ‘good genes as heterozygosity” hypothesis, by investigating if 2 potential categories of ‘good genes’ – multilocus heterozygostity (MLH) and Major Histocompatibility Complex (MHC) genes, affect male fitness components, and epigamic traits. The results showed that: 1) male epigamic traits predicted no. of grandoffspring, but not MS or RS; 2) high-fitness males had high no. of grandoffspring, with sons, but not daughters, having high RS; 3) MLH was heritable and predicted fitness measured as no. of grandoffspring, but not epigamic traits, MS or RS. Taken together, the results highlight that inferring fitness benefits on RS may be incomplete or misleading. Incorporating further generations into studies on sexual selection provide more reliable estimations of fitness.The work contained within this thesis was founded by National Science Centre, grant no. UMO-2013/10/M/NZ8/00253 (‘Testowanie przewagi selekcyjnej nowych alleli MHC w półnaturalnych populacjach gupika, Poecillia reticulata’, Harmonia) awarded to prof. Jacek Radwan and grant no. UMO-2017/25/N/NZ8/00296 (‘Czy atrakcyjne samce gupików mają więcej wnuków? Testowanie kluczowych hipotez doboru płciowego’, Preludium) awarded to the author of this thesis
Worldwide (status, development and) impact assessment of geoportals
No full textAt this moment, numerous (catalogue) geoportals have been established and it is expected that many more geoportals will be implemented in the future. To the best of our knowledge, not many status, development and impact assessment studies have been performed with regard to all these initiatives (certainly not on a worldwide scale). It is very important to know what the main developments and impacts of these facilities are to justify all costs, efforts and time to implement these geoportals and to improve their effectiveness and efficiency.
For this reason, a survey was undertaken (November 2003 - April 2004) in order to assess the worldwide (status, developments and) impacts. The survey consisted of 21questions and was sent to all known geoportal coordinators. In total 428 coordinators were contacted.
105 coordinators completed the survey. They were mainly coordinating international, national/federal and state geoportals in Europe, Australia and USA/Canada (only a few were coordinating Caribbean, African and Asian ones). The results were aggregated for the whole world.
The main results are that the implementation of geoportals is a global activity, that the use of geoportals and spatial data will increase, that more services will be provided and new services will be introduced within the next 5 years. As the main drawbacks for implementation are considered: institutional problems, lack of specialized data managers and data standardization. Moreover, it seems that geoportals (of the developed world) have a positive impact on society. These impacts are mainly economic in nature.April 16-21, 200
The role of access policies on the Development of local SDIs: the Special Role of Utilities
No full textWithin the context of Spatial data infrastructures (SDI) access-to-government-data policies are important for the existence and successful use of the data, and the success of the SDI itself. Many researches have attempted to assess the success of access policies for public sector (geographic) information. Most compare the open access approach of the United States federal government with the cost recovery models in other countries, and conclude that the open access policy is more successful. Consistently, most research recommend nations toconvert cost recovery policies into open access policies. The SDI hierarchy of global, regional, national, state, local and corporate SDIs, however, suggests that success of a specific policy option at one SDI level does not necessarily apply to other levels of SDIs.Therefore, although at first sight the accomplished researches provide convincing evidence for the success of the open access model at the national (or regional) level, they appear to have some deficiencies for application to the local levels of SDIs. The frequently cited researches underestimate the role cost recovery policies may have in the availability of spatial framework data at the local levels of SDI. Through an analysis of the large-scale topographic datasets in three jurisdictions in Europe and two states in the United States, this paper provides insights in the technical and non-technical characteristics of these data, and in the role private or semi-public utilities may play at the local SDI levels. The paper will show that cost recovery policies may be more beneficial for SDI development at the local levels than current research has suggested.OLD Geo-information and Land Developmen
Intracranial haemorrhage associated with cerebral infections: A review
No full textWe present a review of the different viral, bacterial, parasitic and fungal infections that are associated with intracranial haemorrhages. We summarize the clinical presentation of the infection and its cerebral complication. We elucidate the pathology and pathophysiology of the haemorrhage as being spontaneous or secondary to vasculitis, thrombosis, embolization or aneurysmal formation. © 2011 Informa Healthcare.AKE JA, 2006, CLIN INFECT DIS, V43, P46; ARGYRIOU A, 2006, SCAND J INFECT DIS, V1, P63; Boudewijns M, 2003, CLIN MICROBIOL INFEC, V9, P222, DOI 10.1046-j.1469-0691.2003.00503.x; BURKE JM, 1985, NEUROLOGY, V35, P1368; Chan KH, 2005, CEREBROVASC DIS, V19, P391, DOI 10.1159-000085568; Chehrenama M, 1997, NEUROLOGY, V48, P520; Chukwudelunzu FE, 2002, EUR J NEUROL, V9, P423, DOI 10.1046-j.1468-1331.2002.00432.x; Cole JW, 2004, STROKE, V35, P51, DOI 10.1161-01.STR.0000105393.57853.11; Connor MD, 2000, STROKE, V31, P2117; DASTUR DK, 1995, RADIOL CLIN N AM, V33, P733; Dubrovsky T, 1998, NEUROLOGY, V51, P560; ELKIND M, 2010, ARCH NEUROL-CHICAGO, V67, pE1; Endo T, 2002, NEUROSURGERY, V50, P1147, DOI 10.1097-00006123-200205000-00039; Erly WK, 1999, AM J NEURORADIOL, V20, P1605; Flint AC, 2005, NEUROLOGY, V64, P391; Gall C, 1999, NEW ENGL J MED, V341, P611, DOI 10.1056-NEJM199908193410814; Gautschi O, 2003, RESPIRATION, V70, P419, DOI 10.1159-000072908; Gkrania-Klotsas Effrossyni, 2008, J Med Case Rep, V2, P387, DOI 10.1186-1752-1947-2-387; Grau AJ, 2005, STROKE, V36, P1501, DOI 10.1161-01.STR.0000170674.45136.80; Heiro M, 2000, ARCH INTERN MED, V160, P2781, DOI 10.1001-archinte.160.18.2781; Hofer M, 2005, ACTA NEUROPATHOL, V109, P226, DOI 10.1007-s00401-004-0930-3; Jacobi C, 2006, EUR J NEUROL, V13, P536, DOI 10.1111-j.1468-1331.2006.01335.x; Jain R, 2003, AM J NEURORADIOL, V24, P971; Kannoth S, 2009, NEUROCRIT CARE, V11, P120, DOI 10.1007-s12028-009-9208-x; KAYA S, 2008, NEUROSURG REV, V1, P337; KIKUTA H, 1993, BLOOD, V82, P3259; KURE K, 1989, Pediatric Pathology, V9, P655; Lim KK, 2009, J CLIN NEUROSCI, V16, P140, DOI 10.1016-j.jocn.2008.02.017; Maniker AH, 1996, SURG NEUROL, V46, P49, DOI 10.1016-0090-3019(96)00030-4; MCGUIRE D, 1999, AIDS KNOWLEDGE BASE, P445; Miyamoto S, 2006, NEUROL MED-CHIR, V46, P348, DOI 10.2176-nmc.46.348; Mochan A, 2003, STROKE, V34, P10, DOI 10.1161-01.STR.0000043821.35051.FA; Modi G, 2008, J NEUROL NEUROSUR PS, V79, P44, DOI 10.1136-jnnp.2006.108878; MUHPATRA AK, 1988, J ASSOC PHYSICIAN I, V36, P237; MURUGAVEL K, 1989, POSTGRAD MED J, V65, P236; Nigro G, 2002, PRENATAL DIAG, V22, P558, DOI 10.1002-pd.366; Ortiz JU, 2004, ULTRASOUND OBST GYN, V23, P402, DOI 10.1002-uog.1021; Pinto AN, 1996, STROKE, V27, P538; Piovesan EJ, 1997, ARQ NEURO-PSIQUIAT, V55, P126; Rich AR, 1933, B JOHNS HOPKINS HOSP, V52, P5; Scheid R, 2003, EUR J NEUROL, V10, P99, DOI 10.1046-j.1468-1331.2003.00541.x; SCULLY RE, 1996, NEW ENGL J MED, V335, P1587; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002-ana.410140404; Sundaram C, 2007, J CLIN NEUROSCI, V14, P882, DOI 10.1016-j.jocn.2006.05.014; Takeda H, 2002, NEUROL MED-CHIR, V42, P361, DOI 10.2176-nmc.42.361; Uesugi T, 2006, INTERNAL MED, V45, P1193, DOI 10.2169-internalmedicine.45.6116; Vejjajiva A, 1978, Clin Exp Neurol, V15, P92; WIJDICKS EFM, 1991, ANN NEUROL, V29, P683, DOI 10.1002-ana.410290620; Yanagihara C, 2003, INTERNAL MED, V42, P1244, DOI 10.2169-internalmedicine.42.1244; Yeh STY, 2003, J EMERG MED, V25, P265, DOI 10.1016-S0736-4679(03)00200-2; Yoneda H, 2005, CEREBROVASC DIS, V19, P209, DOI 10.1159-00008388422
- …
